



President: Dr Mary McGraw, Bristol Royal Hospital for Children
Tel: 0117 342 8879 Fax: 0117 342 8810 E mail: mary.mcgraw@UHBristol.nhs.uk

Secretary: Dr Sally Feather, Leeds General Infirmary Leeds
Te: 0113 3925640 Fax 01133925129 E mail: sally.feather@leedsth.nhs.uk

Treasurer: Dr Judith van der Voort, University Hospital of Wales, Cardiff
Tel: 02920 744919 Fax: 02920 744822
E-mail: Judith.VanDerVoort@Cardiffandvale.wales.nhs.uk

www.bapn.org

**Minutes of BAPN Executive meeting
Friday November 18th 10.00-13.00
Royal College of Paediatrics and Child Health**

Present

Mary McGraw (MMG)
Peter Houtman (PH)
Sally Feather (SF)
Maggie Fitzpatrick (MMF)
Simon Waller (SW)
Wesley Hayes (WH)
Moin Saleem (MS)
Leah Krischock (LK) (teleconference)
David Milford (DM) (teleconference)

Apologies

Judith van der Voort
Milos Ognjanovic (MO)

1. Minutes of last meeting

These were taken to be a true record of last meeting and are available on BAPN website.

2. Matters arising

a) Atypical HUS commissioning

Updated information regarding atypical HUS bid was received by MMG and was forwarded to EC committee following September meeting. Eculizumab has been removed from application and is due to be considered in a separate process. The application is due to be considered in June 2012. Provisional approval for Eculizumab has been given by EMA and full approval should be available by end of the year. Eculizumab is currently available from some PCTs but not others. Eculizumab is currently not licensed and hence cannot be considered by NICE. When we receive notification that Eculizumab has been licensed the BAPN should notify Amelia Chang at RCPCH to request Eculizumab be considered by NICE (**Action SF**)

Since it is likely that BAPN members will be applying to use Eculizumab from multiple PCTs it would be useful for them to be able to access information from other centres. (**Action SF to contact Sally Johnson and Carol Inward to ask for copies of information on Eculizumab for submitting to local D and T plus PCT**)

b) Baxter dialysis machine software

Baxter have stated that they received advice from paediatric nephrologists to develop the new software which uses patient weight and requires overriding of safety features in order to achieve optimal dialysis in infants. Correspondence is ongoing. MMG has written to Baxter to confirm which paediatric nephrologists were consulted and will enquire at BAPN AGM if anyone in UK has been involved (Action MMG).

c) Discontinuation of Kimal 8 and 10F lines

It would appear that there is conflicting information about this. Currently the BAPN EC understands that Kimal is not planning to discontinue these lines.

d) Discontinuation of metolazone

MMG is in correspondence with MRHSA regarding metolazone. A further communication from the company producing metolazone is expected later this year.

3) Workplans

The workplan copy updated in September 2011 was reviewed. A new workplan for 2012 will need to be produced at March EC meeting. (Action SF)

A discussion was held around the activity of the clinical services committee as the EC has been unable to seek verification that this important committee has met. MMG has not received a response from requests to MO for updates.

The consultant workforce planning document was due to be updated by the clinical services committee. It was agreed that it would be helpful to produce a

document combining consultant manpower per unit together with national planned retirements in next 2 and 5 years, together with trainees likely to obtain CCTs in next 2 and 5 years. The document would be anonymised with respect to CCT and retirement dates and would then be available on BAPN website (**Action SF, MMF and LK**).

4 Agenda items

a) Winter meeting

The programme for BAPN Winter meeting has been agreed. It was suggested that during the 2 hour AGM slots there would be 2 extended presentations: Research (MS) and CSAC (MMF) each 30 minutes allowing 60 minutes for rest of AGM items. Agenda items for Winter meeting need to be requested from BAPN membership (Action SF, as part of November eNews).

In addition, it would be helpful for all EC members to provide a report in advance of the meeting (this could also be used for the BAPN Annual Report, 2011), hence allowing shorter reports during the AGM meeting. (Action SF to request reports from rest of EC).

b) Proposed BAPN honorary members: Alan Watson. Tim Chambers and Mark Taylor were ratified by the committee and will be announced at Winter meeting.

c) Annual report

See 4a. (Action SF to contact EC to provide individual annual reports).

d) Route to membership

MMG has been in correspondence with MCI who are currently scrutinising their databases of membership.

A new process of membership has been agreed:

An application form for membership can be obtained from MCI, via Renal Association website. This should be filled in by candidate (including financial details) and should be signed by proposer and seconder (who should be BAPN members). The form should then be returned to MCI. MCI will then forward forms for ratification at BAPN EC twice a year (March and November). It was noted that since the forms do not include CV for scrutiny by EC, responsibility lies with proposer and seconder. The new membership process will be raised at AGM (Action SF).

Different categories of membership were discussed including the SPIN trainee and it was considered that all trainees should be charged the same amount as they all have access to same training days and information.;

5. Treasurer's report

The financial update report (enclosed with agenda) was reviewed by EC.

6. Secretary's report (SF)

a) BRS

SF has attended BRS meetings. However SF had received communication in the last week that BRS did not intend to have a paediatric session at forthcoming BRS conference (BAPN EC had planned a session focussed on Nephrology Networks document). BAPN EC was disappointed with this news. SF also raised multidisciplinary paediatric nephrology input into the BRS/BAPN as both organisations only include paediatric medical input in their membership currently. (Action SF to raise with BRS and BAPN membership).

b) SPIN member

Elizabeth Evans was ratified as a SPIN member of BAPN (Action SF to contact her). In addition, PH is aware of 8 additional SPIN members. It was agreed that prospectively the new membership process would be used. See 4d

PH has been very active in developing SPIN network and has produced a SPIN newsletter. This needs to be circulated (Action SF to liaise with PH).

7. Registry and Audit Committee

The report was enclosed with agenda and was reviewed.

8. Clinical standards and guidelines committee (DM)

Wesley Hayes has been welcomed onto the committee as new trainee representative. Unfortunately MO has not attended committee meetings (Action DM to contact MO regarding this).

Paediatric nephrology is working on a number of NICE guidelines. DM is now representing paediatric nephrology in the acute kidney injury NICE guidelines. Meeta Malik and Leah Krischock are developing immunosuppression guidelines. Rukshana Shroff has attended phosphate and bone metabolism group.

Hypertension guidelines are on the BAPN website.

Renal Association is producing a new set of adult guidelines and DM has organised paediatric nephrology consultant colleagues to produce paediatric addendum to each of adult guidelines.

MMG asked for input into NICE TA158 on use of ostelmaivir, amantadine and zanamivir for prophylaxis of influenza.

9. Research (MS)

Four trainee bursaries were awarded this time (advertised in eNews).

Four consumer representatives are now involved in work of renal Clinical studies group. MS is attempting to develop a clinical research strategy document to set out priorities. Minutes of the CSG are available on BAPN website.

A number of studies are in development. Funding has been obtained for Rituximab study (Ania Koziell) and Hypertension in transplantation (Manish Sinha). The PREDNOS study has started recruiting.

Another three groups have been added to Radar portfolio. Radar website is undergoing further development. Renal Patient view should be soon linked to upload information to Radar. MPGN study is in development but can still be recruited through links to Radar.

MS attended meeting with industry; aiming to encourage industry to consider UK for clinical trials. CSG is aiming to be the main point of contact for industry led clinical trials in UK.

MS has completed three years as CSG chair. He will check with CSG whether he can carry on for another year as CSG chair in order to align this with BAPN research secretary post.

10. Clinical Services Committee

Concern was raised that this committee may still not have met as there are no minutes that have been submitted for the website. Concern was also expressed that EC had received no information about two items on the agenda within the remit of this committee as the Chair had not attended the last 2 meetings nor provided an update. The BAPN EC agreed approach for non-attendance at EC meetings is present in November 2010 minutes. (Action MMG to contact MO).

11. Communication report (LK)

The first meeting of the patient information leaflet project group has taken place at RCPCH. Joint copyright of the leaflets will be BKPA/RCPCH/BAPN. A quick turn around in comments from BAPN membership regarding leaflets will be required. This will be raised at BAPN Winter meeting (Action LK).

12. CSAC (MMG)

Current work is taking place updating the curriculum. Two applicants have applied to paediatric nephrology national grid.

13. Trainees (WH)

Currently there are 13 trainees in paediatric nephrology. Two will be obtaining CCT next year. The next trainee day is January 26-27 in Nottingham. Trainees hope to get involved in guidelines with consultant lead.

14. Consultations

The list of consultations responded to was reviewed.

15. ACCEA awards

Four applications were received within timescale and forwarded to RCPCH. It remains unclear whether ACCEA process will occur this year.

16. External committee update

MMG had attended RA and JSC committees.

SW updated on Kidney Alliance. The meetings focus mainly on adult nephrology. Currently discussion surrounds funding of dialysis away from base. World kidney day is due to occur next year and will be a smaller event focussed in transplantation.

17. Meetings 2011-2012

2012 BAPN executive meetings: Friday 29th June, Friday 21st September, Friday 30th November 2012

BAPN winter meeting Friday 9th December (Birmingham)

British Renal Society meeting 1-3 May 2012 (Manchester)

BAPN AGM Tuesday 12th June at Renal Association meeting (Gateshead)

Renal Association meeting 11-14 June 2012 (Gateshead)

RCPCH conference 22-24 May 2012 (Glasgow)

18. Teleconference facilities are available at RCPCH and will be used when possible for BAPN EC meetings.

19. Date of next Executive meeting: Friday 30th March 10.00-13.00 RCPCH